Prevalence of Isolated Anti-HBc IgG Positivity in Patients Scheduled for Immunosuppressive Therapy

Abstract

Introduction and Aim: This study aimed to investigate the frequency of isolated antiHBc-IgG positivity in immunosuppressed patients. Material and Method: Between January 2020 and October 2022, 100 patients who underwent hepatitis B virus (HBV) screening for HBsAg, antiHBc-IgG, and anti-HBs, and were indicated for oral antiviral prophylaxis treatment, were icluded in the study. Results: Of the patients included in the study, 58 (58%) were male, with an average age of 47.9 ± 13.8 years (19-76 years). Seven patients had chronic HBV infection with HBsAg and antiHBs-IgG positivity, 77 patients had recovered (naturally acquired) HBV infection with negative HBsAg, positive antiHBc-IgG, and antiHBs positivity, while 16 patients showed isolated antiHBc-IgG positivity. Conclusion: The frequency of isolated anti-HBc-IgG positivity in patients scheduled for immunosuppressive therapy is quite significant, at one in sixteen patients. In addition to HBsAg and anti-HBs, anti-HBc-IgG should also be tested in patients scheduled for immunosuppressive therapy.

Keywords

• immunsuppression
• HbsAg
• anti-HBc-IgG

İmmünsüpresif Tedavi Uygulanması Planlanan Hastalarda İzole Anti-HBc IgG Pozitifliğinin Görülme Sıklığı

Abstract

Giriş ve Amaç: İmmunsüprese hastalarda izole antiHBc-IgG pozitiflik sıklığının araştırılması amaçlanmıştır. Gereç ve Yöntemler: Ocak 2020 Ekim 2022 yılları arasında immünsüpresif tedavi planlanan ve oral antiviral tedavi profilaksi tedavi endikasyonu konulan hastalarda hepatit B virüs (HBV) taraması için HBsAg, antiHBc-IgG ve anti-HBs bakılan 100 hasta çalışmaya alındı. Bulgular: Çalışmaya alınan hastaların 58 tanesi (%58) erkek, yaş ortalaması 47.9 ± 13.8 (19-76 yaş) idi. 7 hastada HBsAg ve antiHBs-IgG pozitif kronik HBV enfeksiyonu, 77 hastada HBsAg (-), antiHBc-IgG ve antiHBs pozitif iyileşmiş (doğal bağışık) HBV enfeksiyonu saptanırken, 16 hastada izole antiHBc-IgG pozitifliği saptandı. Sonuç: Immünsüpresif tedavi planlanan hastalarda izole antiHBc-IgG pozitifliği sıklığı hiçte azımsanmayacak düzeyde onaltı hastada bir pozitiftir. İmmünsüpresif tedavi planlanan hastalarda HBsAg ve antiHBs yanında mutlaka antiHBc-IgG’de bakılmalıdır.

Keywords

• immünsüpresyon
• HBsAg
• antiHBc-IgG

References

1. Soriano V, González R, Barea L, et al. Occult hepatitis B infection - unveiling clinical burden and new diagnostic strategies. Expert Rev Gastroenterol Hepatol. 2026 Feb;20(2):71-80. doi: 10.1080/17474124.2025.2611857.
2. Baghbanian M, Halvani M, Roghani HS, et al. Prevalence Of Occult Hepatıtıs B Infectıon In Iranıan Cancer Patıents Before Chemotherapy Treatment. Arq Gastroenterol. 2016 Jul-Sep;53(3):175-9. doi: 10.1590/S0004- 28032016000300010.
3. He P, Zhang P, Fang Y, et al. The role of HBV cccDNA in occult hepatitis B virus infection. Mol Cell Biochem. 2023 Oct;478(10):2297-2307. doi: 10.1007/ s11010-023-04660-z.
4. Mahmoudvand S, Shokri S, Mirzaei H, et al. Frequency of Hepatitis B Virus infection among Patients before Chemotherapy Treatment. Asian Pac J Cancer Prev. 2021 Sep 1;22(9):2939-2944. doi: 10.31557/ APJCP.2021.22.9.2939.
5. UYANIKOĞLU A, SERT U, NAR H, et al. Occult Hepatitis B Reactivation After Chemoteraphy: A Case Report. Viral Hepatitis Journal. 2015; 21(2): 56-58.
6. Ali FS, Nguyen MH, Hernaez R, et al. AGA Clinical Practice Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation in At-Risk Individuals. Gastroenterology. 2025 Feb;168(2):267-284. doi: 10.1053/j. gastro.2024.11.008.
7. Yang Y, Xing H, Wu G, et al. Global prevalence of occult hepatitis B virus infection in HBcAb-positive individuals: a systematic review and meta-analysis. Sci Rep. 2025 Dec 21;15(1):44244. doi: 10.1038/s41598-025-23207-4.
8. Tozun N, Ozdogan O, Cakaloglu Y, et al. Seroprevalence of hepatitis B and C virus infections and risk factors in Turkey: a fieldwork TURHEP study. Clin Microbiol Infect. 2015 Nov;21(11):1020-6. doi: 10.1016/j. cmi.2015.06.028.

9. Üçbilek E, Yıldırım AE, Ellik Z, et al. Changing Trends in the Etiology of Cirrhosis in Türkiye: A Multicenter Nationwide Study. Turk J Gastroenterol. 2024 Sep 2;35(10):772-777. doi: 10.5152/tjg.2024.23572.
10. Im YR, Jagdish R, Leith D, et al. Prevalence of occult hepatitis B virus infection in adults: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022 Oct;7(10):932-942. doi: 10.1016/S2468-1253(22)00201-1.
11. Su PY, Huang CW, Zeng YH, et al. Prevalence of seropositive occult hepatitis B virus infection among patients received chemotherapy in Taiwan: A retrospective study. J Formos Med Assoc. 2025 Nov 7:S0929-6646(25)00597-2. doi: 10.1016/j.jfma.2025.11.008. Epub ahead of print. PMID: 41206272.